STENTYS : Agenda of financial events 2013

Regulatory News:

STENTYS (FR0010949404 - STNT), a medical technology company commercializing in Europe the world's first and only Self-Apposing^® stent to treat acute myocardial infarction (AMI), announced today its preliminary financial agenda for 2013.

Event		Date *
Q4 Full Year Sales 2012		24 January 2013
Full-Year Results 2012 **		28 March 2013
Q1 Sales 2013		25 April 2013
Q2 Sales 2013		25 July 2013
Half-Year Results 2013		29 August 2013
Q3 Sales 2013		24 October 2013
		Financial year ended 31 December

* Subject to modification
** Press release distributed before the financial markets opening

About STENTYS:

STENTYS is developing and commercializing innovative solutions for the treatment of patients with acute myocardial infarction (AMI, or heart attack) and complex coronary artery disease. STENTYS's Self-Apposing^® Stents are designed to adapt to vessels with ambiguous or fluctuating diameters, particularly in the post-infarction phase, in order to prevent the malapposition problems associated with conventional stents. In the APPOSITION III clinical trial, STENTYS stents demonstrated a very low 30-day mortality rate among 1,000 high-risk AMI patients when compared to recent studies with conventional stents. More information is available at www.stentys.com.

STENTYS is listed on Compartment C of the NYSE Euronext Paris
ISIN: FR0010949404 - Ticker: STNT

STENTYS
Stanislas Piot
CFO
Tel.: [phone]
[e-mail]
Europe: NewCap.
Axelle Vuillermet / Pierre Laurent
Tel.: [phone]
[e-mail]
US: MacDougall Biomedical Communications
Kari Watson, Tel.: [phone]
Christine Labaree, Tel.: [phone]
[e-mail]